JP2024105284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105284A5 JP2024105284A5 JP2024065950A JP2024065950A JP2024105284A5 JP 2024105284 A5 JP2024105284 A5 JP 2024105284A5 JP 2024065950 A JP2024065950 A JP 2024065950A JP 2024065950 A JP2024065950 A JP 2024065950A JP 2024105284 A5 JP2024105284 A5 JP 2024105284A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai construct
- seq
- nucleotides
- pnpla3
- duplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091030071 RNAI Proteins 0.000 claims 40
- 230000009368 gene silencing by RNA Effects 0.000 claims 40
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 230000000692 anti-sense effect Effects 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 16
- 108091081021 Sense strand Proteins 0.000 claims 11
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 claims 10
- 101001129184 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 claims 10
- 108700028369 Alleles Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 4
- 210000005229 liver cell Anatomy 0.000 claims 3
- 108091093094 Glycol nucleic acid Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- KBCBKZHEGSUDBQ-OFBQIVOGSA-N 9-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-1H-purin-6-one Chemical compound CO[C@@]1([C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(O)=NC=NC1=2)O KBCBKZHEGSUDBQ-OFBQIVOGSA-N 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- -1 bicyclic nucleic acid Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777714P | 2018-12-10 | 2018-12-10 | |
| US62/777,714 | 2018-12-10 | ||
| JP2021532216A JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
| PCT/US2019/065481 WO2020123508A2 (en) | 2018-12-10 | 2019-12-10 | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Division JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105284A JP2024105284A (ja) | 2024-08-06 |
| JP2024105284A5 true JP2024105284A5 (enExample) | 2025-03-07 |
Family
ID=69024749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Pending JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
| JP2024065950A Pending JP2024105284A (ja) | 2018-12-10 | 2024-04-16 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Pending JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20220017906A1 (enExample) |
| EP (1) | EP3894555A2 (enExample) |
| JP (2) | JP2022511550A (enExample) |
| KR (1) | KR20210102932A (enExample) |
| CN (1) | CN113166761B (enExample) |
| AR (1) | AR117297A1 (enExample) |
| AU (1) | AU2019396419A1 (enExample) |
| BR (1) | BR112021011061A2 (enExample) |
| CA (1) | CA3121510A1 (enExample) |
| CL (1) | CL2021001489A1 (enExample) |
| CO (1) | CO2021008997A2 (enExample) |
| CR (1) | CR20210371A (enExample) |
| EA (1) | EA202191629A1 (enExample) |
| IL (1) | IL283473A (enExample) |
| JO (1) | JOP20210142A1 (enExample) |
| MX (1) | MX2021006784A (enExample) |
| NZ (1) | NZ776661A (enExample) |
| PE (1) | PE20211225A1 (enExample) |
| PH (1) | PH12021551326A1 (enExample) |
| SG (1) | SG11202105711SA (enExample) |
| TW (1) | TW202039843A (enExample) |
| UY (1) | UY38503A (enExample) |
| WO (1) | WO2020123508A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI723986B (zh) | 2015-04-13 | 2021-04-11 | 美商阿尼拉製藥公司 | 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法 |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| US12084662B2 (en) * | 2021-04-14 | 2024-09-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating PNPLA3 expression |
| WO2022256395A1 (en) * | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| KR20240112993A (ko) * | 2021-09-01 | 2024-07-19 | 알리고스 테라퓨틱스 인코포레이티드 | Pnpla3-표적화 짧은 간섭 rna(sirna) 분자 및 이의 용도 |
| CA3259147A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | NUCLEIC ACID COMPOUNDS |
| EP4630556A1 (en) * | 2022-12-07 | 2025-10-15 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of patatin-like phospholipase domain-containing 3 (pnpla3) |
| CN120712352A (zh) * | 2022-12-19 | 2025-09-26 | 昂拓生物医药有限公司 | 高级rna靶向(arnatar) |
| WO2024173593A1 (en) * | 2023-02-14 | 2024-08-22 | Basecure Therapeutics | Modified double stranded rna agents |
| WO2024182446A2 (en) * | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| AU2024279767A1 (en) * | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| WO1993009668A1 (en) | 1991-11-22 | 1993-05-27 | Affymax Technology N.V. | Combinatorial strategies for polymer synthesis |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| JP2002510319A (ja) | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法 |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| JP4868739B2 (ja) | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 核酸の送達法 |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CA2522637C (en) | 2003-04-17 | 2014-01-21 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| US20160122761A1 (en) | 2013-06-21 | 2016-05-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| CA2976445A1 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2017048620A1 (en) * | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| WO2018223056A1 (en) * | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
-
2019
- 2019-12-10 PE PE2021000850A patent/PE20211225A1/es unknown
- 2019-12-10 CA CA3121510A patent/CA3121510A1/en active Pending
- 2019-12-10 CN CN201980081364.8A patent/CN113166761B/zh active Active
- 2019-12-10 AU AU2019396419A patent/AU2019396419A1/en active Pending
- 2019-12-10 JO JOP/2021/0142A patent/JOP20210142A1/ar unknown
- 2019-12-10 AR ARP190103607A patent/AR117297A1/es unknown
- 2019-12-10 UY UY0001038503A patent/UY38503A/es not_active Application Discontinuation
- 2019-12-10 JP JP2021532216A patent/JP2022511550A/ja active Pending
- 2019-12-10 BR BR112021011061-5A patent/BR112021011061A2/pt unknown
- 2019-12-10 CR CR20210371A patent/CR20210371A/es unknown
- 2019-12-10 EA EA202191629A patent/EA202191629A1/ru unknown
- 2019-12-10 TW TW108145175A patent/TW202039843A/zh unknown
- 2019-12-10 PH PH1/2021/551326A patent/PH12021551326A1/en unknown
- 2019-12-10 EP EP19828524.9A patent/EP3894555A2/en active Pending
- 2019-12-10 MX MX2021006784A patent/MX2021006784A/es unknown
- 2019-12-10 US US17/312,721 patent/US20220017906A1/en active Pending
- 2019-12-10 KR KR1020217021155A patent/KR20210102932A/ko active Pending
- 2019-12-10 WO PCT/US2019/065481 patent/WO2020123508A2/en not_active Ceased
- 2019-12-10 SG SG11202105711SA patent/SG11202105711SA/en unknown
- 2019-12-10 NZ NZ776661A patent/NZ776661A/en unknown
-
2021
- 2021-05-26 IL IL283473A patent/IL283473A/en unknown
- 2021-06-08 CL CL2021001489A patent/CL2021001489A1/es unknown
- 2021-07-08 CO CONC2021/0008997A patent/CO2021008997A2/es unknown
-
2024
- 2024-04-16 JP JP2024065950A patent/JP2024105284A/ja active Pending
-
2025
- 2025-01-17 US US19/029,290 patent/US20250320502A1/en active Pending